Aza Mutia Kehwalla, Suberu Anavami, Balogun Mahmood, Adegbola Goodness, Sankoh Mohamed Alie, Oyediran Thomas, Aderinto Nicholas, Olatunji Gbolahan, Kokori Emmanuel, Agbo Chinonyelum Emmanuel
Johns Hopkins University, Bloomberg School of Public Health, Baltimore, USA.
University of Ilorin, Ilorin, Nigeria.
Med Oncol. 2024 Dec 20;42(1):34. doi: 10.1007/s12032-024-02582-4.
Nanoparticle-based therapies represent a transformative approach to managing gynecological cancers, offering targeted treatment strategies that minimize harm to healthy tissues while maximizing therapeutic efficacy. Despite their potential, implementing these advanced treatments in Africa is needed by a complex interplay of technological, economic, regulatory, and ethical challenges. This paper examines the current landscape of nanoparticle-based therapies, identifying critical barriers to their adoption, including inadequate infrastructure, high costs, and insufficient regulatory frameworks. Technological deficiencies manifest as a need for advanced nanoparticle synthesis, delivery, and diagnostics equipment, impeding research and clinical applications. Economically, the high production costs of nanoparticles, compounded by limited access to advanced diagnostic and treatment facilities, create significant financial barriers for healthcare systems and patients alike. Additionally, the regulatory environment needs to be more cohesive, characterized by a lack of established protocols and expertise to evaluate the unique properties of nanomedicines. However, opportunities for advancement exist through focused research and development initiatives. Targeted drug delivery systems, early detection methods, and immunotherapy integration are promising avenues to enhance treatment outcomes. Collaborative partnerships between African institutions and international research entities, alongside public-private collaborations, could bolster local capabilities in nanomedicine. To facilitate the integration of nanoparticle-based therapies, African governments must prioritize funding for nanomedicine research, create robust regulatory frameworks, and ensure equitable access to these innovative treatments. A concerted effort involving policy reforms, investment, and collaboration is essential for overcoming existing barriers and realizing the full potential of nanoparticle-based therapies in improving health outcomes for gynecological cancer patients across Africa.
基于纳米颗粒的疗法代表了一种治疗妇科癌症的变革性方法，提供了靶向治疗策略，在最大限度提高治疗效果的同时，将对健康组织的损害降至最低。尽管具有潜力，但在非洲实施这些先进治疗受到技术、经济、监管和伦理挑战等复杂相互作用的制约。本文审视了基于纳米颗粒疗法的当前状况，确定了采用这些疗法的关键障碍，包括基础设施不足、成本高昂以及监管框架不完善。技术缺陷表现为需要先进的纳米颗粒合成、递送和诊断设备，这阻碍了研究和临床应用。在经济方面，纳米颗粒的高生产成本，加上获得先进诊断和治疗设施的机会有限，给医疗系统和患者都造成了巨大的经济障碍。此外，监管环境缺乏凝聚力，其特点是缺乏评估纳米药物独特性质的既定方案和专业知识。然而，通过有针对性的研发举措存在取得进展的机会。靶向药物递送系统、早期检测方法以及免疫疗法整合是有望提高治疗效果的途径。非洲机构与国际研究实体之间的合作关系，以及公私合作，可增强当地在纳米医学方面的能力。为促进基于纳米颗粒疗法的整合，非洲各国政府必须优先为纳米医学研究提供资金，建立健全的监管框架，并确保公平获得这些创新治疗方法。涉及政策改革、投资和合作的协同努力对于克服现有障碍以及实现基于纳米颗粒疗法在改善非洲各地妇科癌症患者健康结果方面的全部潜力至关重要。
